Tradename: AREXVY

Proper Name: Respiratory Syncytial Virus Vaccine, Adjuvanted                 

Indication: Indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older.   

Approval Date: 05/03/2023

Manufacturer: GlaxoSmithKline Biologicals


Leave a Reply

Your email address will not be published. Required fields are marked *